Trials / Terminated
TerminatedNCT00508430
ASP 8825 - Study in Patients With Painful Diabetic Polyneuropathy
ASP 8825 Phase II Study-A Double- Blind, Placebo- Controlled Study in Patients With Painful Diabetic Polyneuropathy
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 199 (actual)
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- All
- Age
- 20 Years – 79 Years
- Healthy volunteers
- Not accepted
Summary
To demonstrate the superiority of ASP8825 over placebo and dose response in patients with painful diabetic polyneuropathy.
Detailed description
Three doses of ASP8825 are compared to placebo in efficacy and safety point of view in patients with painful diabetic polyneuropathy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ASP8825 | oral |
| DRUG | Placebo | oral |
Timeline
- Start date
- 2007-07-01
- Primary completion
- 2008-11-01
- Completion
- 2008-11-01
- First posted
- 2007-07-30
- Last updated
- 2008-12-05
Locations
8 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00508430. Inclusion in this directory is not an endorsement.